尹栋,窦克非,杨跃进,徐波,陈珏,刘海波,姚民,秦学文,吴永健,李建军,乔树宾,尤士杰,袁晋青,戴军,陈纪林,高润霖,陈在嘉

• 1:北京市中国医学科学院北京协和医学院国家心血管病中心阜外心血管病医院冠心病中心

摘要(Abstract)：

目的评价冠状动脉长病变患者成功置入Firebird雷帕霉素洗脱支架和Taxus紫杉醇洗脱支架2年后的有效性和安全性。方法本研究入选了2004年4月至2006年10月期间,在阜外心血管病医院行择期经皮冠状动脉介入治疗(PCI)的冠状动脉长病变患者826例。入选患者分为Firebird组(666例)和Taxus组(160例)。随访资料包括术后30天、1年和2年的死亡、心肌梗死、血栓、靶病变血运重建和靶血管血运重建。本研究比较了两组间各种临床事件的累积发生率差异。同时通过倾向性评分调整后的Cox比例风险模型比较两组间的2年临床随访结果。结果两组病变长度[(45.62±15.25)mm比(44.09±13.67)mm]及置入支架长度[(51.22±16.64)mm比(49.63±15.86)mm]相似(P>0.05)。术后2年,Firebird组靶病变血运重建率(3.46%比10.00%,P=0.0005)、靶血管血运重建率(5.42%比11.25%,P=0.008)及MACE发生率(10.99%比20.00%,P=0.002)方面显著低于Taxus组。两组患者术后2年支架肯定或可能血栓形成的发生率差异均无统计学意义。经倾向性评分调整后,与Taxus组相比,应用Firebird支架治疗的患者在术后2年时MACE风险降低(危险比0.622,95%CI:0.401～0.965,P=0.034),而其他临床事件的风险比差异无统计学意义。结论对于冠状动脉长病变患者而言,使用Firebird雷帕霉素洗脱支架MACE发生率较低,而靶病变血运重建率和靶血管血运重建率方面不劣于Taxus紫杉醇洗脱支架,且风险有下降趋势。

关键词(KeyWords)： 冠心病;药物洗脱支架;治疗结果

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 尹栋,窦克非,杨跃进,徐波,陈珏,刘海波,姚民,秦学文,吴永健,李建军,乔树宾,尤士杰,袁晋青,戴军,陈纪林,高润霖,陈在嘉

参考文献(References)：

• [1]Foley DP,Pieper M,Wijns W,et al.The influence of stent length on clinical and angiographic outcome in patients undergoing elective stenting for native coronary artery lesions;final results of the Magic5L Study.Eur Heart J,2001,22:1585-1593.
• [2]Kobayashi Y,De Gregorio J,Kobayashi N,et al.Stented segment length as an independent predictor of restenosis.J Am Coll Cardiol,1999,34:651-659.
• [3]Morice MC,Serruys PW,Sousa JE,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med,2002,346:1773-1780.
• [4]Schmig A,Dibra A,Windecker S,et al.A meta-analysis of16randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.J Am Coll Cardiol,2007,50:1373-1380.
• [5]Cutlip DE,Windecker S,Mehran R,et al.Clinical end points in coronary stent trials:a case for standardized definitions.Circulation,2007,115:2344-2351.
• [6]Kastrati A,Dibra A,Mehilli J,et al.Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents.Circulation,2006,113:2293-2300.
• [7]Windecker S,Remondino A,Eberli FR,et al.Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.N Engl J Med,2005,353:653-662.
• [8]Kim YH,Park SW,Lee SW,et al.Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease.Circulation,2006,114:2148-2153.
• [9]Kim YH,Park SW,Lee CW,et al.Comparison of sirolimus-eluting stent,paclitaxel-eluting stent,and bare metal stent in the treatment of long coronary lesions.Catheter Cardiovasc Interv,2006,67:181-187.
• [10]Lee CW,Park KH,Kim YH,et al.Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions.Am J Cardiol,2006,98:918-922.
• [11]Kim U,Lee SH,Hong GR,et al.Two-year clinical outcomes of patients with long segments drug-eluting stents:comparison of sirolimus-eluting stent with paclitaxel-eluting stent.J Korean Med Sci,2011,26:1299-1304.
• [12]Stettler C,Wandel S,Allemann S,et al.Outcomes associated with drug-eluting and bare-metal stents:a collaborative network meta-analysis.Lancet,2007,370:937-948.
• [13]Rogers CD.Drug-eluting stents:clinical perspectives on drug and design differences.Rev Cardiovasc Med,2005,6:S3-S12.
• [14]Perin EC.Choosing a drug-eluting stent:a comparison between CYPHER and TAXUS.Rev Cardiovasc Med,2005,6:S13-S21.
• [15]Levin AD,Vukmirovic N,Hwang CW,et al.Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel.Proc Natl Acad Sci USA,2004,101:9463-9467.
• [16]Camenzind E,Steg PG,Wijns W.Stent thrombosis late after implantation of first-generation drug-eluting stents:a cause for concern.Circulation,2007,115:1440-1455.
• [17]Ruchin PE,Trabattoni D,Fabbiocchi F,et al.Use of multiple overlapping sirolimus-eluting stents for treatment of long coronary artery lesions:results from a single-center registry in318consecutive patients.Int J Cardiol,2009,134:231-237.
• [18]Schmig A,Dibra A,Windecker S,et al.A meta-analysis of16randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.J Am Coll Cardiol,2007,50:1373-1380.